Matthew T. Murrill

Matthew T. Murrill

Auto-generated profile, based on publicly available information

Matthew T. Murrill

Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ECElizabeth T Chin
Elizabeth T Chin
BHBenjamin Q Huynh
Benjamin Q Huynh
LCLloyd Chapman
Lloyd Chapman
MMMatthew Murrill
Matthew Murrill
SBSanjay Basu
Sanjay Basu
NLNathan C Lo
Nathan C Lo
Routine asymptomatic testing strategies for COVID-19 have been proposed to prevent outbreaks in high-risk healthcare environments. We used simulation modeling to evaluate the optimal frequency of viral testing. We found that routine testing substantially reduces risk of outbreaks, but may need to be as frequent as twice weekly.

6 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ECElizabeth T Chin
Elizabeth T Chin
BHBenjamin Q Huynh
Benjamin Q Huynh
LCLloyd A. C. Chapman
Lloyd A. C. Chapman
MMMatthew Murrill
Matthew Murrill
SBSanjay Basu
Sanjay Basu
NLNathan C Lo
Nathan C Lo
Routine asymptomatic testing strategies for COVID-19 have been proposed to prevent outbreaks in high-risk healthcare environments. We used simulation modeling to evaluate the optimal frequency of viral testing. We found that routine testing substantially reduces risk of outbreaks, but may need to be as frequent as twice weekly.

19 November 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
MMMatthew T Murrill
Matthew T Murrill
GVGustavo E Velásquez
Gustavo E Velásquez
JSJohn D Szumowski
John D Szumowski
APAllison Phillips
Allison Phillips
AKAnnie Kim
Annie Kim
JEJoel D Ernst
Joel D Ernst
Background: Targeted immunotherapies have transformed the treatment of many diseases. However, some increase the risk of tuberculosis (TB) disease. We sought to develop a comprehensive list of targeted immunotherapies with TB infection screening recommendations in US Food and Drug Administration (FDA)-approved prescribing information and compare these recommendations to clinical resources and quality measures. Methods: Through a gray literature review, we identified TB clinical resources and US quality measures. We created a list of targeted immunotherapies and TB infection screening recommendations by analyzing 4 FDA databases. We then evaluated the consistency of screening recommendations in prescribing information, TB clinical resources, and quality measures. Results: We identified 6 TB clinical resources and 1 quality measure for TB infection. While TB infection screening recommendations for tumor necrosis factor (TNF) inhibitors were consistently included, recommendations for other therapies were less consistent. Through FDA database analyses, we identified 269 targeted immunotherapies, 35 (13%) of which had TB infection screening recommendations in prescribing information, including all therapies targeting TNF and several interleukins (IL); however, therapies targeting IL-6, Janus-associated kinase, and others had variable recommendations. Significant discordance in screening recommendations for immunotherapies was further identified when comparing prescribing information, clinical resources, and quality measures. Conclusions: The number and targets of immunotherapies are rapidly evolving resulting in challenges with creating up-to-date and consistent TB infection screening recommendations. Inconsistent recommendations in clinical resources may contribute to gaps in TB preventive care. Harmonized recommendations and additional epidemiologic studies of TB disease risk with the use of these agents are needed.

5 March 2025 in Journal of Immigrant and Minority Health
Verified
Journal Article
Open access
PDF file
MMMatthew T. Murrill
Matthew T. Murrill
KSKatya Salcedo
Katya Salcedo
CTCynthia A Tschampl
Cynthia A Tschampl
NANisha Ahamed
Nisha Ahamed
ECElinor S. Coates
Elinor S. Coates
PSPriya B Shete
Priya B Shete
Despite being preventable, tuberculosis (TB) continues to affect thousands of individuals in the US with an increasing incidence every year since the COVID-19 pandemic. Critical to TB elimination efforts is the scale-up of screening and treatment for the estimated 13 million Americans with TB infection. For the Medicare population, the implementation of TB preventive services is hampered by the lack of clear coverage of TB infection screening. Despite a consistent US Preventive Services Task Force (USPSTF) recommendation since 1996, TB infection screening does not have a Medicare national coverage determination, which would ensure consistent coverage across the US. All other USPSTF recommended preventive services for Medicare recipients have a national coverage determination, a broadly applicable clinical quality measure or are medications generally covered through Medicare Part D. The lack of a national coverage determination for TB infection screening is crucially a health equity issue with TB disproportionally affecting non-US-born and minoritized US-born persons. To address this important barrier to TB prevention, a request to Medicare for a national coverage determination for TB screening was submitted in early 2024.

24 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
PSPriya B Shete
Priya B Shete
MMMatthew T Murrill
Matthew T Murrill
KTKatharine M Tatum
Katharine M Tatum
AAAmina Ahmed
Amina Ahmed
KAKaylynn Aiona
Kaylynn Aiona
TATracy L Ayers
Tracy L Ayers
Background: Treating asymptomatic tuberculosis (TB) infection prevents TB disease and is critical for TB elimination in the United States (U.S.). In the U.S., TB disease disproportionately affects those born outside of the U.S. The quality of TB preventive care in primary care settings for non-U.S.-born populations is poorly characterized. We aimed to measure gaps in TB preventive care among non-U.S.-born persons receiving primary care at community health clinics across the U.S. Method: We conducted a retrospective cohort study at 12 community health clinics in the U.S. Per clinic, individual-level demographic and TB clinical data were extracted for approximately 700 non-U.S.-born persons aged ≥18 years seeking care between June and December 2019. We constructed a care cascade describing gaps in TB infection testing and treatment and used multivariable mixed effects logistic models to evaluate associations between individual and clinic-level characteristics and observed gaps. Results: Among 8460 non-U.S.-born individuals included, 68% were female, and the median age was 50 years (interquartile range 38–63). Of those included, 2765 (33%) had a TB infection test ordered. Among 1022 with a positive test, 787 (77%) were diagnosed with TB infection, of whom 377 (48%) were offered preventive treatment. Among 173 who were treated at study clinics, 141 (82%) completed treatment. Conclusions: Gaps in testing and treatment initiation for non-U.S.-born individuals were pervasive at the 12 community health clinics in this study. Research is needed to identify strategies that increase TB preventive care among populations who face the disproportionate burden of disease. Article summary: In this multi-site study of U.S. community health clinics, substantial gaps in tuberculosis infection testing and treatment initiation were identified for non-U.S.-born persons, a population that bears the disproportionate burden of TB disease in the U.S.

10 October 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
JCJeffrey I Campbell
Jeffrey I Campbell
MBMeredith B Brooks
Meredith B Brooks
LMLeonardo Martinez
Leonardo Martinez
MMMatthew Murrill
Matthew Murrill
PSPranay Sinha
Pranay Sinha
KJKaren R Jacobson
Karen R Jacobson
Background: Interferon γ release assays (IGRAs) are the preferred test for tuberculosis infection in the United States. Their results can fluctuate from positive to negative (reversion), but there is limited information about who does or should receive repeat testing in routine clinical care. Methods: We performed a retrospective cohort study of all individuals with a positive IGRA result in a US community health organization network (OCHIN). We characterized the frequency and predictors of repeat testing and reversion. We used published recommendations to classify repeat IGRAs as “likely,” “possibly,” and “probably not” indicated, and we estimated repeat IGRA overuse and underuse. Results: Among 65 728 individuals with a positive IGRA result, 8978 (13.7%) had ≥1 subsequent test. Of the 8174 second tests with full results available for analysis, 6176 (75.6%) remained positive, 1904 (23.3%) reverted to negative, and 94 (1.2%) were uninterpretable. Lower odds of reversion were associated with higher initial Antigen minus Nil (Ag-Nil) value (adjusted odds ratio, 0.38 [95% confidence interval, .32–.45] for Ag-Nil 0.70 to <1.00, and 0.06 [.05–.07] for Ag-Nil ≥1.00 vs 0.35 [vs Ag-Nil 0.35 to <0.70 IU/mL]), and birth in a country with versus birth in a country without elevated tuberculosis incidence (adjusted odds ratio, 0.59 [95% confidence interval, .52–.67]). Of all repeat tests, 40.0% were likely indicated, 9.0% were possibly indicated, and 51.0% were probably not indicated. Conclusions: Approximately 1 in 7 individuals with positive IGRA results had repeat testing. Most repeat tests were probably not indicated according to our utilization classification, whereas nearly half of individuals without a repeat test may have benefited from one.